Malignancies after Chimeric Antigen Receptor T Cell Therapy.

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• CAR-T cell therapy is a groundbreaking treatment for relapsed/refractory (R/R) B cell malignancies.
• Concerns have arisen regarding the development of second primary malignancies (SPMs) post-CAR-T therapy.

Purpose of the Study:

• To review the incidence and characteristics of SPMs, including second myeloid neoplasms (SMNs) and second non-hematologic malignancies (SNHMs), and T cell cancers after CAR-T therapy.
• To evaluate the risk-benefit profile of CAR-T cell therapy in the context of potential SPMs.

Main Methods:

• Literature review of studies reporting SPMs after CAR-T cell therapy.
• Analysis of incidence rates for SMNs, SNHMs, and T cell malignancies.
• Discussion of factors potentially contributing to SPM development.

Main Results:

• SPM incidence ranges from 2.3% to 11.3%, with higher rates in older patients and those with extensive prior therapies.
• SMNs (e.g., myelodysplastic syndrome) and SNHMs occur at varying rates.
• T cell cancers are rare (0.03%–1%), with challenging causal attribution to CAR-T therapy.

Conclusions:

• The therapeutic advantages of CAR-T cell therapy for specific hematologic malignancies currently outweigh the observed risks of SPMs.
• Further research is necessary to differentiate the impact of CAR-T therapy from other factors contributing to SPM development.